System Is Designed to Provide Researchers With Better Data Earlier
in the Drug Discovery Process
ALAMEDA, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) announced today the launch of its IVIS(R) 3D Imaging System,
the first commercial three-dimensional biophotonic imaging system, on display
at the Fourth Annual Meeting of the Society for Molecular Imaging (SMI) in
Cologne, Germany.
Leveraging Xenogen's expertise and intellectual property in biophotonic
imaging, the company's IVIS 3D Imaging System is designed to help expedite
drug discovery and development, and significantly reduce the cost and time to
market for new therapies. As the most advanced system Xenogen offers, it is
designed to provide even higher quality, more predictive data earlier in the
drug discovery and development process.
Evaluation units of the IVIS 3D systems have been installed at several
medical institutions, including the Childrens Hospital Los Angeles (Los
Angeles, Calif.) and the Hospital for Sick Children (Toronto, Canada).
"Xenogen's new three-dimensional system enables us to see what's happening
to cells inside a mouse, from multiple views and in real time," said Mark
Henkelman, professor, Departments of Medical Biophysics and Medical Imaging,
Canada Research Chair in Imaging, and director, Mouse Imaging Centre, Hospital
for Sick Children. "It is an extremely sensitive camera, and it's now the
only way to get data on patterns of emitted light in animals, data that we
didn't have before. This technology will help us understand gene expression in
mice and thus, better predict gene expression in humans."
Xenogen's non-invasive imaging systems enables scientists to better
visualize, track and understand biological processes in living animals, in
real time. The technology incorporates luciferase, the enzyme that makes
fireflies and some bacteria glow, into living animals. Illuminating
biological processes allows real-time visual exploration and analysis of gene
expression, cellular pathways, drug/target interactions and the mechanism of
action of drugs.
Xenogen's IVIS 3D Imaging System provides a full three-dimensional diffuse
tomographic analysis of bioluminescent light sources in living animals as well
as two-dimensional multi-view fluorescent imaging capabilities. The system
captures and processes numerous views/orientations taken around the mouse to
provide researchers with better spatial representations of the light sources
(e.g., cancer metastases, inflammatory markers). It is designed to enable
researchers to more accurately pinpoint where and when a drug candidate has an
effect on or is affected by a normal or disease process. The detailed surface
topography measurements provided by the IVIS 3D Imaging System are ideal for
co-registering with other modalities such as CT and MRI.
"Leading biotechnology and pharmaceutical companies use our technology to
accelerate pre-clinical drug development, and we believe biophotonic imaging
technology is quickly becoming a research standard," said Pamela R. Contag,
Ph.D., president of Xenogen Corporation. "As leaders in biophotonic imaging
technology, we believe the three-dimensional attributes of our newest and most
sophisticated biophotonic imaging system significantly advance the field."
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology provides higher quality in vivo data earlier in the
drug discovery and development process. VivoVision(TM) Solutions improve
discovery and pre-clinical research in multiple therapeutic areas.
VivoVision(TM) Biosciences represents more than 15 years of experience in the
creation and characterization of animal models, including genetic
modifications, comprehensive phenotyping, compound profiling and custom design
and production of light producing cells, microorganisms and animals.
More information is available at http://www.xenogen.com. Xenogen(R), Living
Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
Forward-Looking Statements
This press release contains forward-looking statements regarding the
performance, adoption and intended uses of our imaging products and
technologies. These forward-looking statements are based on our current
expectations, estimates and assumptions and are subject to many risks,
uncertainties and unknown future events that could cause actual results to
differ materially. Actual use and results of imaging products and technologies
may differ materially from those set forth in this release due to the risks
and uncertainties inherent in our business, including, without limitation:
our ability to continue to deliver our products on a timely basis; our ability
to enforce our intellectual property rights or operate without infringing or
misappropriating the proprietary rights of others; products, services or
technologies introduced by competing companies; and other risk factors set
forth in our filings with the Securities and Exchange Commission. For a
discussion of these and other factors that could impact the adoption,
performance or use of our imaging products and technologies and cause them to
differ materially from those in the forward-looking statements, please refer
to our recent filings with the Securities and Exchange Commission, including
our most recent quarterly report on Form 10-Q for the quarter ended June 30,
2005. We assume no obligation to update any forward-looking statements or
information, which speak as of their respective dates.
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Pamela R. Contag, Ph.D.
http://profnet.prnewswire.com/ud_public.jsp?userid=513625
David W. Carter
http://profnet.prnewswire.com/ud_public.jsp?userid=513851
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
investors, William A. Albright of Xenogen
Corporation, +1-510-291-6100; or media, Kelly McKenna of Manning
Selvage & Lee, +1-415-278-3318, for Xenogen Corporation
|
